In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S ...

A study by an international team of scientists is raising great hopes for patients suffering from these conditions - Dr.

Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...

When a virus enters the lungs, the immune system has to react fast. The lung maintains its own community of immune cells ...

In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of ...

Sanofi and Kali Therapeutics have signed an exclusive global licence agreement for KT501, a new tri-specific antibody for B ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. By acquiring GSK-founded Ouro Medicines, ...

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms ...

California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in ...

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Life, Inc., a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and ...